Piramal Finance invests Rs 1,100cr in Embassy group's projects

Image
Press Trust of India New Delhi
Last Updated : Jun 07 2017 | 2:48 PM IST
Piramal Enterprises today said it has provided Rs 1,100 crore funds to real estate firm Embassy group for development of housing and commercial projects in Bengaluru, Chennai and Hyderabad.
"Piramal Enterprises through its subsidiary Piramal Finance Ltd has financed the Embassy Group for an amount of Rs 1,100 crore," a company statement said.
The funding has been done to residential and commercial projects in Bengaluru, Chennai and Hyderabad over a span of the last six months, it added.
Piramal Finance first funded Rs 360 crore towards Embassy Residences project in Chennai spread over 25 acres with about 0.3 million sq ft of built up area.
Then it made an investment in Phoenix-Embassy, which is a joint venture between Embassy and Phoenix Group of Hyderabad.
The JV is developing about 1.5 million sq ft of grade-A commercial space in Hyderabad with a potential to develop a further 4 million sq ft.
Later, Piramal Finance has provided Rs 650 crore of growth capital to the Embassy Group.
Bengaluru-based Embassy Group is one of India's largest commercial real estate developers having delivered about 30 million sq ft of commercial office space and around 6 million sq ft of housing.
The Group has a pipeline of about 17 million sq ft of commercial developments across Bengaluru, Hyderabad and Chennai.
Piramal Finance Ltd MD Khushru Jijina said the company has provided Embassy Group with customised financial solutions to scale up presence across both residential and commercial projects.
Embassy group CMD Jitu Virwani said: "We are delighted to be working closely with a large diversified conglomerate like the Piramal Group which is known for its structuring capabilities and quick turnaround time."
He said the company would leverage Piramal Group capabilities as we partner with them on our growth capital requirements going forward."
Piramal Enterprises is one of India's large diversified companies, with a presence in pharma, healthcare insights and analytics and financial services. Its consolidated revenues were over USD 1.3 billion in financial year 2016-17, with 51 per cent of revenues generated from outside India.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 07 2017 | 2:48 PM IST

Next Story